The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany
MS Treatments
Jahr
Publikationsjahr
2022
Autoren
Autorenliste der Publikation
Koeditz D, Frensch J, Bierbaum M, Ness NH, Ettle B, Vudumula U, Gudala K, Adlard N, Tiwari S, Ziemssen T.
Verlag
Publisher-Information
Mult Scler J Exp Transl Clin. 2022 Mar 29;8(1):20552173221085741.
Link
Zur Publikation (externer Server)
https://doi.org/10.1177/20552173221085741
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Treatments
2022
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis
MS Treatments
Jahr
2024
Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland
MS Treatments
Jahr
2022
Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab
MS Treatments
Jahr
2024
Consensus quality indicators for monitoring multiple sclerosis
MASC
Jahr
2024
Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany
MS Treatments
Jahr
2024